The nasal vaccine against COVID-19

iNCOVACC is a novel adenovirus vectored, intranasal vaccine for COVID-19. It has various advantages over injectable vaccines. Here are a few of them.

The two-drop nasal vaccine, iNCOVACC is manufactured by Bharat Biotech, India. It is a novel adenovirus vectored, intranasal vaccine for COVID-19 that can stimulate a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses. 

How does it work?

The nasal vaccine is delivered through the nose or mouth. It is expected to work on the mucosal lining. Thus, the nasal vaccine prompts an immune response at the entry points of the virus which is mostly the nose and the mouth. This prevents infection at the entry point itself thereby protecting against disease, infection, and transmission. It is referred to as sterilizing immunity. Many studies have found that nasal delivery of vaccines is capable of creating a strong immune response.

Mice, Hamsters and macaques were immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against the SARS-CoV-2 challenge. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways in all these animal models.

Nasal vaccines v/s Injectable vaccines

Nasal vaccines have a proven benefit over injectable vaccines. In the third phase of the clinical trial which was done on 3,000 participants, iNCOVACC showed good immunity with 2 doses given 4 weeks apart.

Advantages of the nasal vaccine

  • An immune response at the site of infection is essential for blocking both infection and transmission of COVID-19.
  • Non-invasive, Needle-free
  • Ease of administration – does not require trained healthcare workers
  • Elimination of needle-associated risks (injuries and infections)
  • High compliance

Nasal vaccine composition

0.5 ml of this nasal vaccine contains NLT 5X10 particles per mL ChAd36-SARS-CoV-S COVID-19 virus (recombinant) including excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, Polysorbate- 80.

Those who have taken Covishield and Covaxin can take the nasal vaccine as a heterologous booster dose. In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.

The nasal vaccine as a booster dose and not the fourth dose after the booster shot

The nasal vaccine is recommended as a first booster and cannot be administered after one has taken the booster or the precautionary dose. This is because by repeatedly immunizing with a particular type of antigen, the body stops responding or responds poorly. Therefore, taking the nasal vaccine as the fourth dose after taking the booster dose is of no value.

Tags : #COVID19 #Nasalvaccine #Vaccination #VaccineforCOVID19 #iNCOVACC #MadeinIndiavaccine #NasalvaccineforCOVID19 #Medicircle #SmitaKumar

About the Author

Renu Gupta

With a background in Pharmacy which is the clinical health science that links medical science with chemistry, I had the desire to mix creativity to these fields. Medicircle provides me an avenue to apply my training in science and interest in creativity together.

View Profile

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023